Previous Close | 2.1200 |
Open | 2.1300 |
Bid | 2.0900 x 800 |
Ask | 2.7000 x 2200 |
Day's Range | 2.0700 - 2.2893 |
52 Week Range | 1.7400 - 6.8900 |
Volume | |
Avg. Volume | 63,525 |
Market Cap | 59.355M |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4380 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for DYAI
JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the 2022 H.C. Wainwright Global Investment Conferenc
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released 2021 operational and financial results in a press release on May 12, 2022, subsequently filing its 10-Q with the SEC and hosting a conference call with investors. Highlights for the first quarter and to-date include: ➢ Exclusive animal health license agreement with Phibro -
New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical trial application (CTA) to South African Health Products Regulatory Authority (SAHPRA) to support clinical safety of C1 produced proteinsC1 produced COVID-19 monoclonal antibody (mAb) demonstrated broad neutralization and protection agains